Effects of antihypertensive drugs on arterial stiffness

Cardiology in Review

Volumn 20, Issue 5, 2012, Pages 259-263

  Dudenbostel, Tanja ^a   Glasser, Stephen P ^b  

^a Division of Cardiovascular Disease   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

augmentation index; hypertension; pulse contour analysis; pulse wave amplification; pulse wave analysis; pulse wave velocity

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; EPROSARTAN; HYDROCHLOROTHIAZIDE; INDAPAMIDE; INDAPAMIDE PLUS PERINDOPRIL; METOPROLOL SUCCINATE; MINERALOCORTICOID ANTAGONIST; NEBIVOLOL; NITRENDIPINE; PERINDOPRIL; PLACEBO; RAMIPRIL; RENIN INHIBITOR; SPIRONOLACTONE; TELMISARTAN; UNINDEXED DRUG; VALSARTAN;

ANTIHYPERTENSIVE THERAPY; ARTERIAL STIFFNESS; BLOOD PRESSURE MONITORING; CARDIOVASCULAR MORTALITY; DRUG EFFECT; HUMAN; HYPERTENSION; MORBIDITY; NONHUMAN; PATHOPHYSIOLOGY; PREDICTION; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASODILATATION;

ADRENERGIC BETA-AGONISTS; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; HUMANS; HYPERTENSION; META-ANALYSIS AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, MINERALOCORTICOID; RENIN; VASCULAR STIFFNESS;

EID: 84864875950     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31825d0a44     Document Type: Review

References (51)

1. Chobanian AV, Bakris GL, Black HR, et al.; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42 1206-1252.
2. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360 1903-1913.
3. Mancia G, De Backer G, Dominiczak A, et al.; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25 1105-1187. (Pubitemid 46924065)
4. Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus documents developed in collaboration with the American Academy of Neurology, American Geriatrics Society, American Society for Preventive Cardiology, American Society of Hypertension, American Society of Nephrology, Association of Black Cardiologists, and European Society of Hypertension. J Am Coll Cardiol. 2011;57 2037-2114.
5. Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events the Framingham Heart Study. Circulation. 2010;121 505-511.
6. Glasser SP, Dudenbostel T. The global burden of cardiovascular disease The role of endothelial function and arterial elasticity in cardiovascular disease as novel and emerging biomarkers. Curr Cardiovasc Risk Rep. 2011;5 187-195.
7. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al.; Health ABC Study. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation. 2005;111 3384-3390. (Pubitemid 40923391)
8. Laurent S, Boutouyrie P, Asmar R, et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001;37 1236-1241. (Pubitemid 34163575)
9. Najjar SS, Scuteri A, Shetty V, et al. Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol. 2008;51 1377-1383. (Pubitemid 351443076)
10. Cohn JN, Finkelstein S, McVeigh G, et al. Noninvasive pulse wave analysis for the early detection of vascular disease. Hypertension. 1995;26 503-508.
11. Blacher J, Protogerou AD, Safar ME. Large artery stiffness and antihypertensive agents. Curr Pharm Des. 2005;11 3317-3326. (Pubitemid 41300781)
12. Boutouyrie P, Lacolley P, Briet M, et al. Pharmacological modulation of arterial stiffness. Drugs. 2011;71 1689-1701.
13. Czernichow S, Zanchetti A, Turnbull F, et al.; Blood Pressure Lowering Treatment Trialists' Collaboration. The effects of blood pressure reduction and of different blood pressure-lowering regimens on major cardiovascular events according to baseline blood pressure meta-analysis of randomized trials. J Hypertens. 2011;29 4-16.
14. Fyhrquist F, Dahlöf B, Devereux RB, et al.; LIFE Study Group. Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy. Hypertension. 2005;45 580-585. (Pubitemid 40411263)
15. Dahlöf B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA) a multicentre randomised controlled trial. Lancet. 2005;366 895-906. (Pubitemid 41265663)
16. Williams B, Lacy PS, Thom SM, et al.; CAFE InvestigatorsAnglo- Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113 1213-1225.
17. Avolio AP, Van Bortel LM, Boutouyrie P, et al. Role of pulse pressure amplification in arterial hypertension experts' opinion and review of the data. Hypertension. 2009;54 375-383.
18. Laurent S, Cockcroft J, Van Bortel L, et al.; European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness methodological issues and clinical applications. Eur Heart J. 2006;27 2588-2605. (Pubitemid 44627304)
19. Cruickshank K, Riste L, Anderson SG, et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance an integrated index of vascular function? Circulation. 2002;106 2085-2090. (Pubitemid 35192814)
20. Blacher J, Guerin AP, Pannier B, et al. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99 2434-2439. (Pubitemid 29218240)
21. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness a systematic review and meta-analysis. J Am Coll Cardiol. 2010;55 1318-1327.
22. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al. Arterial stiffness and risk of coronary heart disease and stroke the Rotterdam Study. Circulation. 2006;113 657-663.
23. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366 1545-1553. (Pubitemid 41540112)
24. Protogerou A, Blacher J, Stergiou GS, et al. Blood pressure response under chronic antihypertensive drug therapy the role of aortic stiffness in the REASON (Preterax in Regression of Arterial Stiffness in a Controlled Double- Blind) study. J Am Coll Cardiol. 2009;53 445-451.
25. Dhakam Z, McEniery CM, Yasmin, et al. Atenolol and eprosartan differential effects on central blood pressure and aortic pulse wave velocity. Am J Hypertens. 2006;19 214-219. (Pubitemid 43350177)
26. Morgan T, Lauri J, Bertram D, et al. Effect of different antihypertensive drug classes on central aortic pressure. Am J Hypertens. 2004;17 118-123. (Pubitemid 38125127)
27. Mahmud A. Reducing arterial stiffness and wave reflection-Quest of the holy grail? Artery Res 2007;1 13-19. (Pubitemid 46970750)
28. Kampus P, Serg M, Kals J, et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011;57 1122-1128.
29. Protogerou AD, Stergiou GS, Vlachopoulos C, et al. The effect of antihypertensive drugs on central blood pressure beyond peripheral blood pressure. Part II evidence for specific class-effects of antihypertensive drugs on pressure amplification. Curr Pharm Des. 2009;15 272-289.
30. Safar M, Levy B. The response of large arteries to antihypertensive treatment. In O'Rourke M, Safar M, Dzau V, eds. Pharmacological Aspects in Arterial Vasodilation. Philadelphia, PA Lea & Febiger; 1993 2;157-166.
31. Glasser SP, Arnett DK, McVeigh GE, et al. The importance of arterial compliance in cardiovascular drug therapy. J Clin Pharmacol. 1998;38 202-212. (Pubitemid 28144925)
32. Hanselin MR, Saseen JJ, Allen RR, et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58 1008-1013.
33. Kaplan NM. Chlorthalidone versus hydrochlorothiazide a tale of tortoises and a hare. Hypertension. 2011;58 994-995.
34. Asmar RG, London GM, O'Rourke ME, et al.; REASON Project Coordinators and Investigators. Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient a comparison with atenolol. Hypertension. 2001;38 922-926. (Pubitemid 34258694)
35. Mason RP, Walter MF, Trumbore MW, et al. Membrane antioxidant effects of the charged dihydropyridine calcium antagonist amlodipine. J Mol Cell Cardiol. 1999;31 275-281. (Pubitemid 29078237)
36. London GM, Pannier B, Guerin AP, et al. Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994;90 2786-2796.
37. Deary AJ, Schumann AL, Murfet H, et al. Double-blind, placebo-controlled crossover comparison of five classes of antihypertensive drugs. J Hypertens. 2002;20 771-777. (Pubitemid 34913723)
38. Hirata K, Vlachopoulos C, Adji A, et al. Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering' beyond blood pressure or beyond the brachial artery? J Hypertens. 2005;23 551-556. (Pubitemid 40684713)
39. Jiang XJ, O'Rourke MF, Zhang YQ, et al. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens. 2007;25 1095-1099. (Pubitemid 46573130)
40. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens. 2000;14 541-546.
41. Schiffrin EL. Remodeling of resistance arteries in essential hypertension and effects of antihypertensive treatment. Am J Hypertens. 2004;17(12 pt 1) 1192-1200. (Pubitemid 40029420)
42. Lu H, Rateri DL, Feldman DL, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest. 2008;118 984-993. (Pubitemid 351364606)
43. Cherney DZ, Lai V, Scholey JW, et al. Effect of direct renin inhibition on renal hemodynamic function, arterial stiffness, and endothelial function in humans with uncomplicated type 1 diabetes a pilot study. Diabetes Care. 2010;33 361-365.
44. McMurray JJ, Abraham WT, Dickstein K, et al. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail. 2012;14 341-343.
45. ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358 1547-1559.
46. Verma S, Gupta M, Holmes DT, et al. Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. Eur Heart J. 2011;32 2135-2142.
47. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40 117-123. (Pubitemid 34840085)
48. Mahmud A, Feely J. Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. Am J Hypertens. 2005;18 50-55. (Pubitemid 40187349)
49. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53 286-290.
50. de Souza F, Muxfeldt E, Fiszman R, et al. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55 147-152.
51. Savoia C, Touyz RM, Amiri F, et al. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension. 2008;51 432-439. (Pubitemid 351156429)